# Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

> **NCT00461136** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 18 (—)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Aliskiren

## Key facts

- **NCT ID:** NCT00461136
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 18 (—)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461136, "Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00461136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*